港股異動 | 利好疊加 華潤醫藥(3320.HK)續漲逾4%
格隆匯3月29日丨華潤醫藥(3320.HK)股價繼續走強,現報4.18港元,創逾一個月新高,漲幅4.24%,總市值262.6億港元。公司28日公吿稱,附屬華潤三九2021年營業收入同比增長12.34%至153.20億元,歸屬於華潤三九股東的淨利潤同比增長28.13%至20.47億元。東阿阿膠去年營業額按年增長12.89%至38.49億元,純利升917.43%至4.4億元。昨日公司再度發佈公吿稱,附屬公司江中藥業預計今年一季度實現歸屬於江中藥業股東的淨利潤約1.83億元人民幣,同比增長約15%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.